Neurovation Labs is an early stage biotech company focused on diagnosing and treating anxiety disorders and in particular Post-traumatic Stress Disorder (PTSD).
Neurovation Labs grew out of the research performed by Drs. Fanselow and Perusini that sought to understand the cause of PTSD on a physiological level. They discovered that PTSD is manifested through enduring increases in a certain protein (glutamate receptor subunit GluA1) in the amygdala, which is a region of the brain central to fear learning. This protein increase provides the first putative objective indicator of PTSD. The discovery was made using a robust model of PTSD in rodents, stress-enhanced fear learning (SEFL). With the pioneering research successfully completed, Neurovation Labs is currently in development of PTSD detection methods and a companion treatment based on these discoveries.